Teva Naloxone Nasal Spray (naloxone hydrochloride)
Status:
Concluded with an LOI
Manufacturer:
Teva Canada Ltd.
Indication:
Opioid overdose, known or suspected, for emergency use
Last updated October 8, 2024
Status:
Concluded without agreement
Manufacturer:
Paladin Labs Inc.
Indication:
Epilepsy, partial-onset seizures
Last updated October 4, 2024
Status:
Negotiations were not pursued
Manufacturer:
Sobi Canada Inc.
Indication:
Chronic Immune Thrombocytopenia
Last updated October 3, 2024
Status:
Negotiations were not pursued (No supply available in Canada)
Manufacturer:
Novo Nordisk Canada Inc.
Indication:
Growth hormone deficiency
Last updated September 26, 2024
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
Migraine, prevention
Last updated September 25, 2024
Status:
Concluded with an LOI
Manufacturer:
BioCryst Pharmaceuticals Inc.
Indication:
Hereditary Angioedema
Last updated September 12, 2024
Status:
Concluded with an LOI
Manufacturer:
Duchesnay Inc.
Indication:
Contraceptive, oral
Last updated September 11, 2024
Yescarta (axicabtagene ciloleucel)
Status:
Concluded with an LOI
Manufacturer:
Gilead Sciences Canada Inc.
Indication:
Follicular lymphoma (FL), Relapsed or refractory, grade 1, 2 or 3a, in adult patients after two or more lines of systemic therapy
Last updated September 6, 2024
Yescarta (axicabtagene ciloleucel)
Status:
Concluded with an LOI
Manufacturer:
Gilead Sciences Canada Inc.
Indication:
Diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL), in adult patients, that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy
Last updated September 6, 2024
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
Von Hippel-Lindau (VHL) disease in adult patients who require therapy for associated non-metastatic renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or non-metastatic pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.
Last updated August 30, 2024